Today's health news spans pediatric mental health crises, drug approvals for children, cancer treatment advances, and emerging concerns about research funding and regulatory decisions impacting medical innovation.

Over 1 million children in England have active mental health referrals in 2024-2025, with more than 60,000 waiting over 2 years for support, highlighting a critical backlog in pediatric mental health services.

The FDA approved risankizumab for treating moderate-to-severe plaque psoriasis and psoriatic arthritis in children, extending the IL-23 inhibitor's indication beyond its previous adult-only approvals in 2019 and 2022.

AI-assisted point-of-care ultrasound (POCUS) technology now enables nurse practitioners and physician assistants to perform faster bedside cardiac assessments, potentially improving diagnostic speed and accessibility in clinical settings.

Dupilumab demonstrates effectiveness in reducing severe asthma exacerbations in children with type 2 asthma and allergen sensitization, offering improved treatment outcomes for this pediatric patient population.

Mezigdomide triplet therapy shows improved progression-free survival in patients with relapsed or refractory multiple myeloma when combined with carfilzomib and dexamethasone, advancing cancer treatment options.

The European Medicines Agency rejected three therapies (Tacquell, Yartemlea, and Xervyteg) across oncology and transplantation due to concerns over efficacy, safety, and data interpretability.

Researchers warn that terminated federal research grants cause lasting damage beyond funding restoration, with concerns that proposed regulations could allow nonscientific control to permanently influence science policy.

Frailty in rheumatoid arthritis patients correlates with disease severity, fatigue, and comorbidities rather than age alone, suggesting that disease-related factors drive functional decline in RA populations.